Cargando…
(106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma
BACKGROUND: To evaluate (106)Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. METHODS: From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392724/ https://www.ncbi.nlm.nih.gov/pubmed/32727533 http://dx.doi.org/10.1186/s13014-020-01621-4 |
_version_ | 1783564904566882304 |
---|---|
author | Jiang, Ping Purtskhvanidze, Konstantine Kandzia, Gerit Neumann, Dirk Luetzen, Ulf Siebert, Frank-André Roider, Johann Dunst, Juergen |
author_facet | Jiang, Ping Purtskhvanidze, Konstantine Kandzia, Gerit Neumann, Dirk Luetzen, Ulf Siebert, Frank-André Roider, Johann Dunst, Juergen |
author_sort | Jiang, Ping |
collection | PubMed |
description | BACKGROUND: To evaluate (106)Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. METHODS: From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6 mm). The mean dose at the tumor apex was 141.4 Gy (± SD: 12.1 Gy) and 557.7 Gy (± SD: 257.3 Gy) to the sclera. RESULTS: Mean follow-up was 69.5 months (± SD: 53.8 months). Thirty-four patients (87.1%) remained free of recurrence. Twenty-six patients (66.7%) demonstrated a complete tumor regression after a median period of 12 months (3–60 mon.). By the final examination, the visual acuity of 26 patients (66.7%) was better than 20/200, and 12 patients (30.7%) had a visual acuity better than 20/40. Retinopathy was detected in 11 patients (28.2%). After treatments only one patient (5.1%) had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 patients (10.3%). Cataract development was diagnosed in 21 patients (53.8%), and 16 patients (41%) had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5 mm or more. There was no significant difference in local control or in side effects between both groups observed. CONCLUSIONS: Our study proved (106)Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. Our data suggested that this treatment is also suitable for tumors with a depth of more than 5 mm. |
format | Online Article Text |
id | pubmed-7392724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73927242020-08-04 (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma Jiang, Ping Purtskhvanidze, Konstantine Kandzia, Gerit Neumann, Dirk Luetzen, Ulf Siebert, Frank-André Roider, Johann Dunst, Juergen Radiat Oncol Research BACKGROUND: To evaluate (106)Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. METHODS: From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6 mm). The mean dose at the tumor apex was 141.4 Gy (± SD: 12.1 Gy) and 557.7 Gy (± SD: 257.3 Gy) to the sclera. RESULTS: Mean follow-up was 69.5 months (± SD: 53.8 months). Thirty-four patients (87.1%) remained free of recurrence. Twenty-six patients (66.7%) demonstrated a complete tumor regression after a median period of 12 months (3–60 mon.). By the final examination, the visual acuity of 26 patients (66.7%) was better than 20/200, and 12 patients (30.7%) had a visual acuity better than 20/40. Retinopathy was detected in 11 patients (28.2%). After treatments only one patient (5.1%) had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 patients (10.3%). Cataract development was diagnosed in 21 patients (53.8%), and 16 patients (41%) had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5 mm or more. There was no significant difference in local control or in side effects between both groups observed. CONCLUSIONS: Our study proved (106)Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. Our data suggested that this treatment is also suitable for tumors with a depth of more than 5 mm. BioMed Central 2020-07-29 /pmc/articles/PMC7392724/ /pubmed/32727533 http://dx.doi.org/10.1186/s13014-020-01621-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jiang, Ping Purtskhvanidze, Konstantine Kandzia, Gerit Neumann, Dirk Luetzen, Ulf Siebert, Frank-André Roider, Johann Dunst, Juergen (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title | (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title_full | (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title_fullStr | (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title_full_unstemmed | (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title_short | (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
title_sort | (106)ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392724/ https://www.ncbi.nlm.nih.gov/pubmed/32727533 http://dx.doi.org/10.1186/s13014-020-01621-4 |
work_keys_str_mv | AT jiangping 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT purtskhvanidzekonstantine 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT kandziagerit 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT neumanndirk 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT luetzenulf 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT siebertfrankandre 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT roiderjohann 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma AT dunstjuergen 106rutheniumeyeplaquebrachytherapyinthemanagementofmediumsizeduvealmelanoma |